Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral HRS9531 in adults with type 2 diabetes mellitus
CTR20261854Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in type 2 diabetes mellitus (T2DM), sponsored by Fujian Shengdi Pharmaceuticals. Started Jul 2026; status: active.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20261854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261854.